

Children's Mercy Kansas City

SHARE @ Children's Mercy

Posters

4-27-2019

Total and Free Plasma Bilirubin and Clinical Outcomes in Severe Hyperbilirubinemia

Sean M. Riordan

Children's Mercy Hospital

Jean-Baptiste LePichon

Children's Mercy Hospital

Steven Shapiro

Children's Mercy Hospital

Tina Slusher

Fatima Abdullahi

See next page for additional authors

Let us know how access to this publication benefits you

Follow this and additional works at: <https://scholarlyexchange.childrensmercy.org/posters>



Part of the [Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons](#), [International Public Health Commons](#), [Neurology Commons](#), and the [Pediatrics Commons](#)

Recommended Citation

Riordan, Sean M.; LePichon, Jean-Baptiste; Shapiro, Steven; Slusher, Tina; Abdullahi, Fatima; Suleiman, Hafsat M.; Pam, Victor C.; Samuel, Mamu B.; Yilgwan, Christopher S.; Isichei, Christian; and Mohammed, Idris Y., "Total and Free Plasma Bilirubin and Clinical Outcomes in Severe Hyperbilirubinemia" (2019). *Posters*. 83.

<https://scholarlyexchange.childrensmercy.org/posters/83>

This Poster is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Posters by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact hlsteel@cmh.edu.

Authors

Sean M. Riordan, Jean-Baptiste LePichon, Steven Shapiro, Tina Slusher, Fatima Abdullahi, Hafsat M. Suleiman, Victor C. Pam, Mamu B. Samuel, Christopher S. Yilgwan, Christian Isichei, and Idris Y. Mohammed

Total and Free Plasma Bilirubin and Clinical Outcomes in Severe Hyperbilirubinemia

Sean M. Riordan^{1,2,3}, J.B. Le Pichon^{1,2,3}, Steven M. Shapiro^{1,2,3}, Tina Slusher⁴, Fatima Abdullahi⁵, Hafsat M. Suleiman⁵, Victor C. Pam⁶, Mamu B. Samuel⁶, Christopher S. Yilgwan⁶, Christian Isichei⁶, Idris Y. Mohammed⁷

✉ smriordan@cmh.edu

Background: Acute bilirubin encephalopathy (ABE) and kernicterus spectrum disorder (KSD) have become relatively uncommon in high income countries but remain a major cause of morbidity and mortality in low- and middle-income countries

Objective: To better understand the relationship between free (Bf) and total (TB) bilirubin levels and the development of ABE and KSD we followed infants born in three large tertiary centers in northern and central Nigeria (Jos, Kano and Zaria).

Study Design:

- Prospective Cohort Study
- Inclusion Criteria
 - TB ≥ 15 mg/dL
- Exclusion Criteria
 - Active infection
 - Hypoxic ischemic encephalopathy
 - Other metabolic developmental abnormalities

Sample and Data Collection:

- Blood Samples – for DNA extraction
- Serum Samples – For TB and Bf measurement
- Data
 - General demographics
 - G6PD deficiency status
 - Rh disease
 - ABO incompatibility
 - Pregnancy history
- Neurological Assessment at 1, 3, and 6 months
 - Modified Barry-Albright Dystonia + Spasticity Scale
 - Clinical Adaptive Test/Clinical Linguistic and Auditory Milestone Scale (CAT/CLAMS)
- Bilirubin Measurements
 - TB measurement (Total and direct) measured on centrifugation separated serum by the BR2 Bilirubin Stat-Analyzer using the Malloy-Evelyn diazo method at time of collection.
 - Bf and TB measurement measured at Children's Mercy Hospital via the Peroxidase Method (Ahlfors 2000)(Jacobsen and Wennberg 1974)

Results:

- 67 infants enrolled in initial 3 month period
- Peak TB range: 15 – 62.6 mg/dL (256.5 – 1,071 umol/L)
- Bf range: 2.34 – 33.54 nM
- Pearson Correlation of 19 Bf / TB samples did not show a significant correlation ($R^2 = 0.094$)

Conclusions

- [TB] is a poor predictor of toxic [Bf] in these samples
- Hemolysis is a more serious issue than previously anticipated and will require more careful sample collection

Free bilirubin measurements in 3 Nigerian Hospitals over a 3-month period show poor correlation with total bilirubin. However hemolysis proved to be a significant problem.





Figure 1: Non-Hemolyzed samples with reliable Bf readings. Bf and TB readings from CMH. n = 18

Pearson r	0.307
R ²	0.094
P value (two-tailed)	0.201
P value summary	ns


Test Site	Hemolyzed*	Total	Percent Hemolyzed
Zaria	25	27	93%
Jos	49	64	77%
Kano	32	49	65%
Total	106	140	76%

Table 1: Samples were categorized as hemolyzed if the hemoglobin signal exceeded 10% of the bilirubin signal ($A_{578} / A_{460} < 10\%$)


Measurement Reproducibility




Pearson r	0.923
R ²	0.851
P value (two-tailed)	<0.0001
P value summary	****



Pearson r	0.714
R ²	0.509
P value (two-tailed)	<0.0001
P value summary	****



Pearson r	0.623
R ²	0.3881
P value (two-tailed)	0.0005
P value summary	***



Pearson r	0.119
R ²	0.014
P value (two-tailed)	0.405
P value summary	ns

Next Steps:


- Implement new protocols for improved sample collection and minimization of hemolysis
- Expand the sample size and continue with follow up of patients to identify correlation of Bf with severity of KSD

Acknowledgements:

- Research team members in Nigeria involved in consenting, sample collection, storage, and shipping
- Charles Ahlfors for training on TB and Bf testing
- Josh Wheatley for performing TB and Bf testing

References:

- Ahlfors, C. E. (2000). Measurement of plasma unbound unconjugated bilirubin. *Anal Biochem*, 279(2), 130-135. PMID: 10706781
- Jacobsen, J., & Wennberg, R. P. (1974). Determination of unbound bilirubin in the serum of newborns. *Clin Chem*, 20(7), 783. PMID: 4835230



Scan the Code for access to information about this poster's design methodology

